Caris Life Sciences (CAI) Accumulated Expenses (2024 - 2026)

Caris Life Sciences' Accumulated Expenses history runs 3 years deep, the most recent figure standing at $73.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses changed N/A year-over-year to $73.9 million; the TTM figure through Mar 2026 stood at $73.9 million (changed N/A YoY), while the FY2025 annual figure was $87.8 million, up 13.19% from the prior year.
• Accumulated Expenses was $73.9 million for Q1 2026 at Caris Life Sciences, down from $87.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $87.8 million in Q4 2025 to a low of $56.9 million in Q3 2025.
• Historically, Accumulated Expenses has averaged $71.5 million across 3 years, with a median of $73.9 million in 2026.
• Biggest YoY gain for Accumulated Expenses was 13.19% in 2025; the steepest drop was 13.19% in 2025.
• A 3-year view of Accumulated Expenses shows it stood at $77.5 million in 2024, then climbed by 13.19% to $87.8 million in 2025, then dropped by 15.78% to $73.9 million in 2026.
• The last three Accumulated Expenses figures came in at $73.9 million (Q1 2026), $87.8 million (Q4 2025), and $56.9 million (Q3 2025), per Business Quant data.